Monopar Therapeutics Files 8-K
Ticker: MNPR · Form: 8-K · Filed: Oct 22, 2024 · CIK: 1645469
| Field | Detail |
|---|---|
| Company | Monopar Therapeutics (MNPR) |
| Form Type | 8-K |
| Filed Date | Oct 22, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: administrative, corporate-filing
TL;DR
Monopar Therapeutics updated its principal executive office address in an 8-K filing.
AI Summary
On October 22, 2024, Monopar Therapeutics Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 1000 Skokie Blvd, Suite 350, Wilmette, IL 60091. The report does not contain specific financial details or significant events beyond the address update.
Why It Matters
This filing serves as an official notification of the company's principal executive office location. Investors and stakeholders can use this information for official correspondence and to understand the company's operational base.
Risk Assessment
Risk Level: low — The filing is a routine administrative update and does not disclose any new material financial information or strategic changes that would inherently increase risk.
Key Players & Entities
- Monopar Therapeutics Inc. (company) — Registrant
- 1000 Skokie Blvd, Suite 350, Wilmette, IL 60091 (location) — Principal executive offices
- October 22, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report the company's principal executive offices and to serve as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is the new address for Monopar Therapeutics' principal executive offices?
The principal executive offices of Monopar Therapeutics Inc. are located at 1000 Skokie Blvd, Suite 350, Wilmette, IL 60091.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on October 22, 2024.
What is the state of incorporation for Monopar Therapeutics Inc.?
Monopar Therapeutics Inc. is incorporated in Delaware.
What is the trading symbol for Monopar Therapeutics Inc.?
The filing mentions that securities are registered pursuant to Section 12(b) of the Act and lists 'Trading Symbol(s)' but does not specify the symbol for Monopar Therapeutics Inc. in the provided text.
Filing Stats: 432 words · 2 min read · ~1 pages · Grade level 10.8 · Accepted 2024-10-22 08:00:17
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value MNPR The Nasdaq Stock Mar
Filing Documents
- mnpr20241021c_8k.htm (8-K) — 25KB
- ex_735439.htm (EX-99.1) — 10KB
- monologo.jpg (GRAPHIC) — 4KB
- 0001437749-24-031684.txt ( ) — 179KB
- mnpr-20241022.xsd (EX-101.SCH) — 3KB
- mnpr-20241022_def.xml (EX-101.DEF) — 12KB
- mnpr-20241022_lab.xml (EX-101.LAB) — 16KB
- mnpr-20241022_pre.xml (EX-101.PRE) — 12KB
- mnpr20241021c_8k_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On October 22, 2024, Monopar Therapeutics Inc. (Monopar) issued a press release announcing that it is presenting human clinical dosimetry data at the European Association of Nuclear Medicine. The press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits Exhibit No. Description 99.1 Press Release Dated October 22, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Monopar Therapeutics Inc. Date: October 22, 2024 By: /s/ Karthik Radhakrishnan Name: Karthik Radhakrishnan Title: Chief Financial Officer